Led Korro Bio's $85M private placement financing.
Korro Bio is focused on discovering, developing, and commercializing a new class of RNA therapies informed by human genetics and disease biology to improve the lives of patients with debilitating and life-threatening diseases
Korro Bio is focused on discovering, developing, and commercializing a new class of RNA therapies informed by human genetics and disease biology to improve the lives of patients with debilitating and life-threatening diseases. Their proprietary platform, OPERA®, enables precise RNA editing to modulate biological pathways and address complex prevalent diseases.